Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, announces that it has concluded a positive Type C meeting with the US Food and Drug Administration (FDA) for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.
AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open in the UK.
Microbiotica has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.
Watch the recording to see how the BIA Regulatory and Access Community is driving UK life sciences forward through expert insights on ILAP, MHRA initiatives, and collaborative innovation.
Alchemab Therapeutics (Alchemab) today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
Mosaic Therapeutics, Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies, announced the in-licensing of two clinical-stage oncology programs.
On 6 March 2025, just ahead of International Women’s Day, the BioIndustry Association (BIA) hosted the Women in Biotech Cambridge event—a vibrant gathering of trailblazing women shaping the life sciences landscape.
This week’s blog explores the dynamic intersection of life sciences, policy, and innovation. From groundbreaking collaborations in the UK to navigating the shifting IP landscape in North America, I reflect on how our sector continues to lead and adapt in a rapidly changing world.
This latest research builds upon the growing body of evidence demonstrating the unique impact of Brainomix’s AI-powered software to expand access to life-changing stroke treatments across networks.
Precision BioSearch was delighted to partner with Optieum Biotechnologies Inc. (“Optieum”), a biotechnology company focused on discovering and developing innovative CAR-T cell therapies, to secure the appointment of Dr. Dan MacLeod as Chief Scientific Officer.
This week our new BIA UK biotech financing report shows £3.5 billion invested in 2024, I detail the launch of the STVC Fellowship, look at the impact of the proposed US withdrawal from WHO, and news from Davos on groundbreaking AI-driven drug trials by Isomorphic Labs.
The UK’s Cell and Gene Therapy Catapult has published new insights into the advancement of the UK’s cell and gene therapy industry in its 2024 ATMP Clinical Trials Database.
Scancell Holdings plc (AIM: SCLP), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, has achieved significant clinical and commercial milestones in its ModiFY study.
